APA 6th Edition Altarac, S., Cindro, V., Radović, N., Rajković, Z. i Belina, S. (2011). ULOGA ALFA-BLOKATORA KOD KRONIČNOG PROSTATITISA TIPA III. Liječnički vjesnik, 133 (5-6), 0-0. Preuzeto s https://hrcak.srce.hr/171759
MLA 8th Edition Altarac, Silvio, et al. "ULOGA ALFA-BLOKATORA KOD KRONIČNOG PROSTATITISA TIPA III." Liječnički vjesnik, vol. 133, br. 5-6, 2011, str. 0-0. https://hrcak.srce.hr/171759. Citirano 15.10.2019.
Chicago 17th Edition Altarac, Silvio, Vedran Cindro, Nikola Radović, Zoran Rajković i Stanko Belina. "ULOGA ALFA-BLOKATORA KOD KRONIČNOG PROSTATITISA TIPA III." Liječnički vjesnik 133, br. 5-6 (2011): 0-0. https://hrcak.srce.hr/171759
Harvard Altarac, S., et al. (2011). 'ULOGA ALFA-BLOKATORA KOD KRONIČNOG PROSTATITISA TIPA III', Liječnički vjesnik, 133(5-6), str. 0-0. Preuzeto s: https://hrcak.srce.hr/171759 (Datum pristupa: 15.10.2019.)
Vancouver Altarac S, Cindro V, Radović N, Rajković Z, Belina S. ULOGA ALFA-BLOKATORA KOD KRONIČNOG PROSTATITISA TIPA III. Liječnički vjesnik [Internet]. 2011 [pristupljeno 15.10.2019.];133(5-6):0-0. Dostupno na: https://hrcak.srce.hr/171759
IEEE S. Altarac, V. Cindro, N. Radović, Z. Rajković i S. Belina, "ULOGA ALFA-BLOKATORA KOD KRONIČNOG PROSTATITISA TIPA III", Liječnički vjesnik, vol.133, br. 5-6, str. 0-0, 2011. [Online]. Dostupno na: https://hrcak.srce.hr/171759. [Citirano: 15.10.2019.]
Sažetak Studies were identified on internet by searching on address: http://www.ncbi.nlm.nih.gov/pubmed/ with criteria that studies should be placebo-controlled and randomized in trials of alpha-blockers in chronic category III prostatitis evaluated by symptom-score NIH-CPSI. From 13 clinical studies three were excluded because of not using NIH-CPSI, three were in Chinese language and two were congress abstracts. Analysed were five studies with four or five Jadad scale including 563 patients. Alpha-blockers alfuzosin, terazosin, tamsulosin and doxazosin have been used through 6 weeks and 6 months. Better results were accomplished by less selective alpha-blockers alfuzosin, terazosin and doxazosin through 3–6 months in patients having higher NIH-CPSI score and higher voiding score.